Current Issue: June 2026
Feature Article
Clinical Applications of PARP Inhibitors in Breast, Ovarian, and Prostate Cancer: Current Insights and Future Directions
Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as an important therapeutic option for patients with homologous recombination repair (HRR)–deficient cancers, especially those with BRCA1/2 mutations. Since […]
Prostate Cancer In Focus
Targeting Human Kallikrein 2 in Prostate Cancer
H&O What is human kallikrein 2 (KLK2), and what makes it a good target in prostate cancer? MS KLK2 is a membrane-associated protease that is involved […]
Advances in Drug Development
The Development of Second-Generation KRAS Inhibitors
H&O How common are KRAS mutations in patients with various types of cancer? EO Approximately 20% to 25% of patients with cancer will have a RAS […]
CRC in Focus
Targeting BRAF V600E Mutations in Metastatic Colorectal Cancer
H&O How common is BRAF V600E–mutated colorectal cancer (CRC)? SK BRAF V600E mutations occur in approximately 5% to 7% of patients with metastatic CRC. That percentage […]
CLL in Focus
Active Treatment in High-Risk, Early-Stage CLL or SLL
H&O How often do patients present with asymptomatic, early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and how many of these patients experience progression […]
Letter From the Editor
Letter From the Editor: Artificial Education
Cancer is a field that requires continuous education. Nearly all the treatments I use today for my patients with prostate, bladder, or kidney cancer did not […]
Supplements:
Molecular Residual Disease (MRD) Testing: Advancing Clinical Decision-Making in Breast Cancer
Abstract: Circulating tumor DNA (ctDNA) is emerging as a clinically meaningful biomarker across multiple solid tumors, including breast cancer. Advances in personalized, tumor-informed whole-genome sequencing have enabled […]
Clinical Response With Cabozantinib Plus Nivolumab, a First-Line Therapy in Advanced Renal Cell Carcinoma: A Clinical Case Report
In the Clinic . . . SH is a 47-year-old woman with a history of hypothyroidism and menopause who was diagnosed in March 2019 with Fuhrman […]